-+ 0.00%
-+ 0.00%
-+ 0.00%

Zai Lab publishes 2025 annual report

PUBT·04/28/2026 14:28:31
Listen to the news
Zai Lab publishes 2025 annual report
  • Zai Lab published 2025 annual report outlining strategy to expand commercial footprint in Greater China while advancing global R&D pipeline.
  • Portfolio reached seven marketed programs across oncology, immunology, neuroscience, infectious disease, with recent launches including XACDURO in January 2025 and AUGTYRO in December 2024.
  • NRDL access broadened across five products, supporting uptake in key indications such as ovarian cancer, gMG, CABP/ABSSSI, 4L GIST, ROS1+ NSCLC.
  • Pipeline focus shifted toward internally originated assets, led by DLL3-targeting ADC zoci in global Phase 3 for extensive-stage SCLC.
  • Near-term catalysts include planned China launch of KarXT in first half of 2026 following NMPA approval in December 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12131276), on April 28, 2026, and is solely responsible for the information contained therein.